SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN), continuing its strategy to bring the
power of genomics into clinical applications, today announced it has
named one of the world’s top clinical genomics experts to head its
clinical genomics unit. Garret Hampton, PhD, will join as Executive Vice
President of Clinical Genomics for the company, starting January 9, 2017.
“This is a strategically important hire for Illumina,” said Francis
deSouza, President and Chief Executive Officer of Illumina. “Garret has
been on the front lines of oncology and brings deep expertise in
clinical genomics to the leadership team, key to his new role leading
our clinical genomics organization.”
Garret will be responsible for leading the clinical genomics group,
including the reproductive and genetic health and oncology businesses,
regulatory, clinical and medical affairs, CLIA labs, and the Chief
Medical Officer’s organization. He joins Illumina from Genentech, Inc.,
where he was Global Head of Oncology Biomarker Development and Companion
Diagnostics, co-led the Roche Personalized Medicine R&D Initiative and
chaired the Roche/Foundation Medicine Joint R&D Committee. He previously
held scientific and management roles at Celgene Corporation, Genomics
Institute of the Novartis Research Foundation, and University of
California at San Diego. Garret holds a BA in natural sciences and
genetics and MA in natural sciences from Trinity College in Dublin,
Ireland, and a PhD in cancer genetics from Imperial Cancer Research Fund
and the University College London.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical, and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com
and follow @illumina.
This release contains forward-looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are
not limited to, statements we make regarding the expected availability
dates for new products and services and FDA submission dates and
intentions for certain products and services. Important factors that
could cause actual results to differ materially from those in any
forward-looking statements include challenges inherent in developing,
manufacturing, and launching new products and services, and the other
factors that are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms 10-K and
10-Q, or in information disclosed in public conference calls, the date
and time of which are released beforehand. We do not intend to update
any forward-looking statements after the date of this release.